Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

A total of 43% of patients treated with combo regimen survive invasive fungal infection

Publish date:: July 22, 2020

Key clinical point: A voriconazole plus terbinafine combo was associated with significantly increased 28-day survival compared with patients receiving monotherapy.

Major finding: Overall, 43% of patients had a treatment response/stable disease and 53% had a fatal outcome attributed to invasive fungal infection.

Study details: A retrospective review of 41 patients with invasive L. prolificans infection in the Fungiscope Registry diagnosed between Jan. 2008 and Sep. 2019.

Disclosures: The Fungiscope Registry is supported by a wide variety of pharmaceutical and biotechnology companies; the researchers also reported funding from a wide variety of pharmaceutical and biotechnology companies.

Citation:

Jenks JD et al. Clinical Microbiology and Infection. 2020;26:784.e1e784.e5.

This Week's Must Reads

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Three genes could predict congenital Zika infection susceptibility,

‘Excellent short-term outcomes’ seen in HCV+ liver transplants to HCV– recipients,

Must Reads in Invasive fungal infections

Posaconazole prophylaxis was effective in children with ALL undergoing chemotherapy,

Infection with Fusarium is a risk in hematology patients,

Primary immunodeficiency disease patients have high risk of invasive fungal disease,

MicroRNAs can distinguish invasive aspergillosis in lung transplant recipients,

Saliva-controlled sputum culture aids diagnosis of deep pulmonary infections,